Starting in June 2022, TAP has made several equity investments in Faron Pharmaceuticals to "Support Clinical Development of the Bexmarilimab Program for Leukemia Indications."
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function.
The Phase 1/2 BEXMAB study (NCT05428969) investigated bexmarilimab in combination with azacitidine in patients with myelodysplastic syndromes (MDS). Patients were enrolled at both US and Finland sites. The Phase 2 part of the BEXMAB study was conducted in treatment-naïve and HMA-failed MDS patients. The trial has completed enrollment and results have been presented at scientific conferences.
In April 2026, Faron announced a new randomized Phase 2b clinical trial (BEXERA) to begin enrollment in October 2026. The BEXERA trial is a randomized, double-blind, placebo-controlled Phase 2b trial in treatment-naïve HR-MDS. The trial will evaluate bexmarilimab at two doses in combination with azacitidine, compared with placebo plus azacitidine. The trial is expected to enroll 90 participants across sites in North America and Europe. The objective of the trial is to select the recommended Phase 3 dose, and to demonstrate the efficacy and safety of the combination in a randomized, controlled setting to support later registrational filings in frontline HR-MDS.
For more information about Faron, visit www.faron.com/.
Recent News
- June 15, 2026 - presented matured BEXMAB data at EHA 2026 confirming durable efficacy and bone marrow reprogramming in HR-MDS
- April 16, 2026 - announced collaboration with Parexel to support Phase 2b BEXERA trial in treatment-naïve HR-MDS
- April 9, 2026 - published final results of its EUR 40.1 million rights issue, including TAP participation
- March 2, 2026 - Faron and City of Hope in process of developing a Phase 2 investigator-initiated trial in relapsed/refractory MDS
- December 8, 2025 - presented updated BEXMAB data at ASH 2025: deep and durable responses in HR-MDS with favorable safety profile
- June 6, 2025 - presented Phase 2 data from BEXMAB study at ASCO 2025 as oral presentation
- March 3, 2025 - FDA granted Orphan Drug Designation for bexmarilimab in MDS
- December 10, 2024 - presented BEXMAB clinical data at ASH 2024
- August 27, 2024 - announced bexmarilimab granted Fast Track Designation for treatment of MDS in combination with azacitidine by the FDA
- June 20, 2024 - announced the completion of the Offering of approximately EUR 30.7 million
- January 9, 2024 - announced first HMA-failed MDS patient was dosed with bexmarilimab as part of Phase 2 of BEXMAB trial
- October 11, 2023 - announced updated data from the Phase 1/2 BEXMAB study investigating bexmarilimab in combination with standard of care in relapsed/refractory AML and MDS patients having failed hypomethylating agents
- January 27, 2023 - announced results of private placement, supported by new investors and existing shareholders including TAP participation
- June 28, 2022 - announced a private placement to a limited number of institutional and other investors to raise EUR 5 million including the Therapy Acceleration Program (TAP).